الفهرس 
Introduction and aim of the workOnly 14 pages are availabe for public view
 |  | from | 143 |  |  |
| | | from | 143 | | |
Abstract
serum samples and liver biopsies of 117 hcv infected individuals were collected and were classified into two groups according to metavir system (f0-f4): a) group 1 include 62 patient with clinically none significant liver fibrosis (f0-f1).b) group 2 include 55 patient with clinically significant liver fibrosis (f2-f4) fibronectin was identified using sds-polyacrylamide gel electrophoresis and western blot at 90-kda in sera of hcv infected patients with different stages of liver fibrosis. fibronectin concentration (µg/ml) in patients with none significant liver fibrosis (f0-f1) were 317 ± 184 and 587.8 ± 322 in significant liver fibrosis patients (f2-f4).the area under the receiver operating characteristic curve of fibronectin for discriminating chronic hcv patients with none significant liver fibrosis (f0-f1) from those with significant liver fibrosis (f2-f4) and its p value were 0.78 and p<0.0001.the efficiency of fibronectin for discriminating chronic hepatitis c virus patients with none significant liver fibrosis (f0-f1) from those with significant liver fibrosis (f2-f4) was 76%. finally, among the other laboratory biomarkers of liver fibrosis, serum fibronectin (µg/ml) was the most efficient index in the evaluation of the fibrosis. therefore, serum level of fibronectin can be used for discriminating chronic hcv patients with none significant liver fibrosis (f0-f1) from those with significant liver fibrosis (f2-f4).